ClinicalTrials.gg
RecruitingNCT07445412I-GROWtohUpdated Mar 3, 2026

Italian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic Hypertrophy

An observational study in Liver Tumours, Liver Cancer (Primary and Metastatic) and Liver Resection, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna — 9 open to participants now, 9 under way, none of them phase 3. Carcinoma, Hepatocellular · IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Planned enrollment
2nd of 11
2,000 · median 270
Started
2024
with 2 others
Observational
11 of 13
9 open now
Registered
12th of 13
by date

Among the 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2024, is one of 11 observational ones, and was the 12th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

9 of the 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna, or all of them as a file.
02

Study summary

The goal of this national mutlticenter observational study is to learn and describe trends over time in the use of techniques for inducing hepatic hypertrophy in Italy. Patients will be treated according to the current clinical practice of the participating centers and will be observed from the moment of recruitment and throughout their stay. Information on vital status will be collected, as far as possible, for up to 5 years after surgery in order to record any events that occur in a timely manner. There are also plans to retrospectively collect data on patients who underwent hypertrophic techniques in the previous 10 years, in order to establish a historical cohort for each center that can be used for comparison with the prospective cohort.

03

Conditions studied

  • Liver Tumours
  • Liver Cancer (Primary and Metastatic)
  • Liver Resection
  • Liver Hypertrophy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes patients with potentially resectable primary or secondary liver tumors. An anatomical-pathological situation is defined as potentially resectable if a small residual liver requires regenerative procedures prior to liver resection to avoid the risk of post-resection liver failure

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 or older
  • Obtaining
  • Patients with liver neoplasia (benign or malignant) and with a future liver remnant volume deemed insufficient (\<20%-40%) by the local multidisciplinary team

Exclusion criteria

Exclusion Criteria:

  • pregnant or breastfeeding woman
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
2,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Prospective cohort

    The clinical information from prospectice cohort will be collected from the moment of recruitment , as far as possible, for up to 5 years after surgery in order to record any events that occur in a timely manner.

  • Retrospective Cohort

    There is also a plan to collect data on patients who underwent hypertrophic techniques in the previous 10 years, in order to establish a historical cohort for each center that can be used for comparison with the prospective cohort.

06

What researchers measure

Primary outcomes

  1. Describe the temporal trends in the use of techniques for inducing hepatic hypertrophy in Italy

    Time frame: through study completion, an average of 1 year

  2. compare the techniques used in terms of function and volumetric hypertrophy

    Time frame: through study completion, an average of 1 year

  3. compare the techniques used in terms of drop-out

    Time frame: through study completion, an average of 1 year

  4. compare the techniques used in terms of 90-day mortality

    Time frame: through study completion, an average of 1 year

  5. compare the techniques used in terms of long-term survival

    Time frame: through study completion, an average of 1 year

  6. compare the techniques used in terms of disease-free survival

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2039, 180 months after the start.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 180 months is above that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
Mar 3, 2026
StartActual
Oct 22, 2024
Primary completionEst.
Oct 2039
CompletionEst.
Apr 2040
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07445412
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Oct 22, 2024
Primary completion
Oct 2039 (estimated)
Completion
Apr 2040 (estimated)
Last update
Mar 3, 2026

Study contacts

Elio Jovine, MD
Contact
elio.jovine@aosp.bo.it
+39 3356468200
Matteo Serenari, MD
Contact
matteo.serenari@aosp.bo.it
+39 3289277643
Elio Jovine, MD
principal investigator · IRCCS Policlinico di Sant'Orsola - Malpighi (Bologna, Italy)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion